USV Private Limited exists because a vegetable vendor’s son refused to accept the limits of his circumstances. Dr. Vithal Balkrishna Gandhi, born in 1896, funded his own education through sponsorships, earned a medical degree, studied at Columbia University, fought for Indian independence, and then in 1961 founded a pharmaceutical company through a technology-transfer agreement with USV&P Inc. of the United States. Today, USV is a $610 million private company that holds the number-one position in India’s oral anti-diabetic market, still led by the Gandhi family three generations later.
Dr. Vithal Balkrishna Gandhi was born in 1896 into modest circumstances. His father was a vegetable vendor. Despite this, Gandhi pursued education relentlessly, funding his studies through sponsorships and eventually earning a medical degree. He then travelled to the United States, where he studied at Columbia University. He was also a freedom fighter, participating in India’s independence movement, a generation of Indians for whom building institutions was inseparable from building a nation.
In 1961, Dr. Gandhi founded what would become USV through a technology-transfer partnership with USV&P Inc., an American pharmaceutical company. The original name, U.S. Vitamins & Pharmaceutical Corporation (India) Ltd, reflected this American partnership. The technology transfer gave the young Indian company access to formulation know-how and manufacturing processes that would have taken years to develop independently.
Dr. Gandhi passed away in 1969, just eight years after founding the company. But the institution he built proved durable. USV remained a private, family-controlled company across the following decades, never listing on public exchanges. That decision, to stay private rather than pursue the capital and visibility of a public listing, shaped everything about USV’s culture: long-term thinking, conservative financial management, and a willingness to invest patiently in therapeutic areas where the company could build genuine expertise.
USV’s defining achievement is its position in India’s diabetes and cardiovascular markets. The company is the number-one player in India’s oral anti-diabetic segment by both prescriptions and value. In a country where diabetes prevalence is among the highest in the world and growing rapidly, this is not a niche position. It is a central franchise in one of the largest and most important therapeutic categories in Indian healthcare.
In cardiovascular medicine, USV holds the number-one position by prescriptions and ranks fourth by value. The prescription-leadership metric is significant: it means that more Indian physicians write USV’s brand names on their prescription pads than any competitor’s. This kind of physician trust is earned over decades through consistent product quality, reliable supply, and sustained medical-representative engagement. It cannot be acquired or replicated quickly.
The strategic logic of concentrating in diabetes and cardiovascular is straightforward. These are chronic conditions requiring daily medication, often for life. Once a physician prescribes a particular brand and the patient tolerates it well, switching is rare. This creates a recurring revenue base with high patient retention, the pharmaceutical equivalent of subscription revenue. USV built its entire commercial model around this dynamic, investing disproportionately in the therapeutic relationships and physician trust required to win the initial prescription.
USV is now led by the third generation of the Gandhi family. Chairperson Leena Gandhi Tewari, who holds an MBA from Boston University, is the granddaughter of founder Dr. V.B. Gandhi. Managing Director Prashant Tewari brings engineering and management credentials from IIT Kanpur (B.Tech) and Cornell University (MS). Board member Dr. Aneesha Gandhi Tewari holds a PhD in Molecular Biology from MIT.
The educational credentials of the leadership are worth noting not for their prestige but for what they represent: a family that has consistently invested in scientific and managerial training across generations. A Columbia-educated physician founded the company; his granddaughter chairs it with a business degree; her daughter serves on the board with a doctorate in molecular biology from one of the world’s leading research universities. The intellectual trajectory mirrors the company’s own evolution from a technology-transfer operation to an independent pharmaceutical enterprise.
Family control has allowed USV to make decisions that publicly listed companies might find difficult. Staying private means no quarterly earnings calls, no analyst expectations to manage, and no pressure to maximise short-term returns. It also means USV can invest in long-horizon projects, such as building a biologics manufacturing capability, without explaining the near-term margin impact to public shareholders. The trade-off is less access to capital markets, but for a $610 million company generating healthy margins in chronic-disease therapeutics, internal cash generation has proven sufficient.
USV operates 7 manufacturing plants: 4 formulation facilities, 2 API (active pharmaceutical ingredient) plants, and 1 dedicated biologics facility. All plants carry FDA accreditation, a level of regulatory compliance that demonstrates USV’s manufacturing operations meet the standards required for the world’s most demanding pharmaceutical markets.
The inclusion of a dedicated biologics plant is notable. Biologics manufacturing, producing complex protein-based therapies through living cell systems, requires fundamentally different infrastructure and expertise from traditional small-molecule pharmaceutical production. Building a biologics facility signals USV’s intent to expand beyond its traditional oral-dosage-form stronghold into the higher-complexity, higher-value segment of biosimilar and biologic therapies.
The vertical integration across APIs and finished formulations gives USV supply-chain control that contract-manufacturing-dependent companies lack. By producing its own active ingredients, USV is less exposed to the price volatility and supply disruptions that periodically affect the global API market. For a company whose core business depends on uninterrupted supply of daily-use chronic-disease medications, this reliability is not merely a cost advantage. It is a clinical necessity: patients on diabetes or cardiovascular medications cannot afford supply interruptions.
With approximately 5,800 employees headquartered in Mumbai, USV maintains the lean, focused organisation that private ownership enables. The workforce is concentrated on the therapeutic areas where USV competes, without the diversification into unrelated businesses that some larger companies pursue.
Sources: USV Private Limited corporate disclosures and company history. IQVIA prescription and market share data for Indian pharmaceutical market. US FDA facility accreditation records. Industry publications and company biographical materials.